In the News

BioSpace | May 1, 2021
jCyte Announces Promising Phase IIb Results for Allogeneic Retinal Stem Cell Therapy

Opthalmology Times | Oct 5, 2020
Intravitreally injected hRPCs improve vision in retinitis pigmentosa cases

Financial Times | Sept 14, 2020
Cell therapy opens up new cure horizons

Retinal Physician | Sept 1, 2020
Trial data on gene therapy, proposed Medicare cuts, FDA clearance of an AI diagnostic for DR, and more.

Optical Journal | Aug 13, 2020
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa

The Stem Cellar  | July 29, 2020
Encouraging news for treatment targeting retinitis pigmentosa

Eyewire News | July 27, 2020
jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosa

Endpoints News | July 27, 2020
Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

Review of Ophthalmology | July 9, 2020
Regenerative Medicine In Ophthalmology

UCI | June 4, 2020
UCI Startup Company jCyte Partners with Santen Pharmaceutical

Orange County Business Journal | May 27, 2020
Biotech jCyte Inks $252M Licensing Deal

Healio | May 14, 2020
Santen to commercialize jCyte’s jCell therapy outside US

The Stem Cellar | May 11, 2020
A Clear Vision for the Future

Global Genes | May 11, 2020
JCyte Licenses Ex-US Rights to Retinitis Pigmentosa Cell Therapy to Santen for $252 Million

Pharmaceutical Business Review | May 11, 2020
JCyte signs ex-US licensing deal with Santen for retinal disease therapy

The Pharma Letter | May 9, 2020
jCyte out-licenses rare vision disorder treatment for $252 million

Biocentury | May 8, 2020
jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

Bioworld | May 8, 2020
Santen inks $252M license to Jcyte ocular cell therapy

Media Contact

 

Robert Beathard
Sr. Vice President, Corporate Development
media@jcyte.com